1-苯甲酰基-1-甲硫基甲醇与硫脲和芳胺的反应研究

1-苯甲酰基-1-甲硫基甲醇(2)与硫脲(3a)和芳基取代硫脲(3b-3i)在弱酸性条件下回流反应1h,得到5-苯基咪唑啉-2-硫酮-4-酮(4a)和1-芳基-5-苯基咪唑啉-2-硫酮-4-酮(4b-4i),产率72%～89%.而化合物2与芳胺(5a-5f)在弱碱性条件下回流反应3h,则得到2-芳胺基-2-甲硫基苯乙酮(6a-6f),产率为64%～88%.     

2-芳基-3,4-二氮杂芴酮和2-芳基-3,4-二氮杂螺二芴衍生物的合成

水合茚三酮与芳甲基酮、水合肼缩合环化制得2-芳基-3,4-二氮杂芴酮(2); 2经还原得2-芳基-3,4-二氮杂芴(3).2与2-溴联苯格氏试剂反应得到中间体叔醇(4); 4在酸性条件下关环合成了2-芳基-3,4-二氮杂螺二芴,其结构经1H NMR,13C NMR和元素分析表征.     

1-芳酰基-4-(5-芳基-2-呋喃甲酰基)氨基硫脲衍生物的合成及其生物活性

酰胺基硫脲;芳基酰肼;1-芳酰基-4-(5-芳基-2-呋喃甲酰基)氨基硫脲衍生物的合成及其生物活性     

1-芳基-2-丙酮的合成研究

以芳香胺为原料, 经重氮化和改进的Meerwein芳基取代反应, 合成了一系列的1-芳基-2-丙酮, 其中1-(3,5-二三氟甲基苯基)-2-丙酮是一个新化合物. 改进后的方法简化了合成步骤, 提高了收率, 可方便地用于在苯环上具有不同取代基的芳基丙酮的合成.     

2-(1-苯基-3-芳基吡唑-4-基)-3-芳酰氨基-4-噻唑啉酮的合成

1-苯基-3-芳基-4-甲酰基吡唑与芳酰肼在乙醇中回流,缩合所得的腙在巯基乙酸作用下,合环得到2-(1-苯基-3-芳基吡唑-4-基)-3-芳酰氨基-4-噻唑啉酮类化合物,其结构经IR,MS,1HNMR谱和元素分析确证。     

3-芳基-4-[4''-(2,2,6,6-四甲基哌啶-1-氧)]-1,2,4-三唑啉-5-硫酮类的合成

本文用芳酰肼和2,2,6,6-四甲基-4-异硫氰基-哌啶-1-氧以无水乙醇为溶剂,在氩气保护下反应,制得八种1-芳酰基-4-[4'(2,2,6,6-四甲基哌啶-1-氧)]氨基硫脲(1),继而研究1在几种碱催化下脱水的环化反应。试验结果表明,只有在1mol的K2CO3水溶液中,才能较满意地使1环化,得到预期的3-芳基-4-(4'-2,2, 6,6-四甲基哌啶-1-氧)-1,2,4-三唑啉-5 硫酮。     

反式2,3-二芳基取代-1-氨基环丙烷羧酸的合成及其结构研究

芳香醛与马尿酸在Erlenmeyer反应条件下缩合得到(Z)-2-苯基4芳亚甲基-5(4H)-噁唑酮，然后在室温下与芳基重氮甲烷通过非对映高立体选择性1，3-偶极环加成反应得到螺环化合物，再经醇解开环、水解去保护合成出反式2，3-二芳基-1-氨基取代环丙烷羧酸．通过元素分析，IR，^1H NMR，^13C NMR，MS和X射线晶体测定，确认了它们的化学结构和立体构型．实验结果表明，通过选择适当的芳香醛和芳基重氮甲烷，可以得到不同立体构型的反式2，3-二芳基取代-1-氨基环丙烷羧酸．     

水中3-甲基-6-氨基-5-氰基-4-芳基-1-苯基-1，4-二氢吡喃[2，3-c]吡唑的洁净合成

在水溶剂中并有三乙基苄基氯化铵（TEBA）存在下，取代芳亚甲基丙二腈与3- 甲基-1-苯基-2-吡唑啉-5-酮缩合成为3-甲基-6-氨基-5-氰基-4-芳基-1-苯基-1， 4-二氢吡喃[2,3-c]吡唑，此法为相应化合物的合成提供了一种快速、方便、高效 和洁净的方法。     

四氢叶酸辅酶模型化合物的研究I.碘化 1 ,2 -二甲基 - 3-芳磺酰基 -△~2 -咪唑啉的合成及其性质

合成了四氢叶酸辅酶甲酸态的3个模型化合物,即碘化1,2-二甲基-3-芳磺酰基(芳基=p-CH3C6H4,C6H5,p-ClC6H4)-△2-咪唑啉,研究了其还原和水解反应。     

2-芳基乙烯基苯并噻唑的催化合成及其紫外光谱的取代基效应

甲基苯并噻唑;固相催化剂;缩合反应;2-芳基乙烯基苯并噻唑的催化合成及其紫外光谱的取代基效应     

Synthesis and antibacterial activity of hydroxylated 2-arylbenzothiazole derivatives

Abstract

N-acyliminium reagents formed in situ from benzothiazole and alkyl chloroformates react with hydroxyarenes in a Friedel-Crafts manner, providing access to 2-(hydroxyaryl)-benzothiazolines with antibacterial properties.     

Unexpected regioselectivity in the reaction between cycloalkenyl-1-diazenes and thioamides: useful entry to fused cycloalkyl-thiazoline and cycloalkyl-thiazoline-pyrazole systems

New tetrahydro-3aH-cyclopenta[d][1,3]thiazolines and hexahydro-1,3-benzothiazolines were obtained in satisfactory yields by reaction of cycloalkenyl-1-diazenes with thioamides. These thiazolines were converted into unknown fused cycloalkyl-thiazoline-pyrazole systems.     

Syntheses of Heterocycles from the Sodium Salts of 3-(1-Adamantyl)-1-hydroxy-1-propen-3-one and 4-(1-Adamantyl)-1-hydroxy-1-buten-3-one

The interaction of the sodium salts of 3-(1-adamantyl)-1-hydroxy-1-propen-3-one and 4-(1-adamantyl)-1-hydroxy-1-buten-3-one with hydroxylamine, hydrazine, and guanidine leads to the synthesis of 5-(1-adamantyl)-5-hydroxy- and 5-(1-adamantylmethyl)-5-hydroxy-2-isoxazolines, 3-(1-adamantyl)- and 3-(1-adamantylmethyl)pyrazoles, 3-(1-adamantyl)-2-phenylpyrazole, and 4-(1-adamantyl)-2-amino- and 4-(1-adamantylmethyl)-2-aminopyrimidines.     

Synthesis and properties of esters of benzothiazolylamino(imino)propionic acids

Reaction of 2-alkylaminothiazoles with methyl acrylate leads predominantly to the formation of N-alkyl-N-(-methoxycarbonylethyl)-2-aminobenzothiazoles on boiling or to 2-(alkylimino)-3-(-methoxycarbonylethyl)-benzothiazolines at room temperature. A complex mixture of products was obtained from unsubstituted 2-aminobenzothiazole and methyl acrylate, of which the main was 2-oxo-3,4-dihydro-2H-pyrimido[2,1-b]benzothiazole. Complete or partial destruction of the benzothiazolines occurred on heating to 140°C.Institute of Plant Chemistry, Uzbek Academy of Sciences, Tashkent 700170. Translated from Khimiya Geterotsiklicheskikh Soedinenii, No. 7, pp. 981–987, July, 1997.     

Optically active antifungal azoles. XII. Synthesis and antifungal activity of the water-soluble prodrugs of 1-[(1R,2R)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-3-[4-(1H-1-tetrazolyl)phenyl]-2-imidazolidinone

1-[(1R,2R)-2-(2,4-Difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-3-[4-(1H-1-tetrazolyl)phenyl]-2-imidazolidinone (1: TAK-456) was selected as a candidate for clinical trials, but since its water-solubility was insufficient for an injectable formulation, the quaternary triazolium salts 2 were designed as water-soluble prodrugs. Among the prodrugs prepared, 4-acetoxymethyl-1-[(2R,3R)-2-(2,4-difluorophenyl)-2-hydroxy-3-[2-oxo-3-[4-(1H-1-terazolyl)phenyl]-1-imidazolidinyl]butyl]-1H-1,2,4-triazolium chloride (2a: TAK-457) was selected as an injectable candidate for clinical trials based on the results of evaluations on solubility, stability, hemolytic effect and in vivo antifungal activities.     

1-(1-Phthalazinyl)- and 1-(4methoxyphenyl)-6,6dimethyl-4oxo-4,5,6,7-tetrahydroindazole

2-(1-Phthalazinylhydrazino)methylene-(IIIa) or 2-(1-phthalazinylhydrazino)ethylidene-5,5-dimethyl-1,3-cyclohexanediones (IIIb) were prepared from 1-hydrazinophthalazine and 2 formyl- or 2-acetyldimedone. Cyclization of IIIb in the presence ofp- TsOH gave 1-(1-phthalazinyl)3, 6, 6-trimethyl-4-oxo-4, 5, 6, 7-tetrahydroindazole. Reaction of 4-methoxyphenylhydrazine with 2 formyl- and 2-acetyidimedone gave the corresponding 1-(4methoxyphenyl)-4-oxo-4, 5, 6, 7-tetrahydroindazole. In the case of 2 -formyldimedone the intermediate 2-(4methoxyphenylhydrazinomethylene)-5, 5-dimethyl-1,3-cyclohexanedione was isolated.Riga Technological University, Riga LV-1658. Translated from Khimiya Geterotsiklicheskikh Soedinenii, No. 5, pp. 708–710, May, 1996. Original article submitted December 31, 1995.     

Synthesis of 1-(4-butoxyphenyl)-1-cyclohexyl-3-(4-arylpiperazin-1-yl)-2-phenylpropan-1-ols and their dihydrochlorides

Aminomethylation of 1-(4-butoxyphenyl)-2-phenylethanone with paraformaldehyde and substituted piperazines in ethanol medium results in 1-(4-butoxyphenyl)-3-(4-R-piperazin-1-yl)-2-phenylpropan-1-ones. The latter react with cyclohexylmagnesium halide to give 1-(4-butoxyphenyl)-1-cyclohexyl-3-(4-arylpiperazin-1-yl)-2-phenylpropan-1-ols. Reduction of the prepared β-aminoketones with lithium aluminum hydride in absolute diethyl ether leads to the secondary aminopropanols. The prepared compounds could be converted into the corresponding dihydrochlorides.     

1-(2-Quinoxalyl)-, 1-[3,5-Di(trifluoromethyl)phenyl]-, 1-(2-Carboxyphenyl)-, and 1-Ethoxycarbonyl-4-oxo-4,5,6,7-tetrahydroindazoles

The corresponding 1-(2-quinoxalyl)-, 1-[3,5-di(trifluoromethyl)phenyl]-, and 1-ethoxycarbonyl-3-methyl-4-oxo-4,5,6,7-tetrahydroindazoles have been obtained from reactions of 2-acetyl-1,3-cyclohexanedione, its 5,5-dimethyl and 5-(2-furyl) derivatives, with 2-hydrazinoquinoxaline, 3,5-di(trifluoromethyl)phenylhydrazine, and ethoxycarbonylhydrazine. On interaction with ethoxycarbonylhydrazine the intermediate 2-[1-(-ethoxycarbonyl)hydrazino]ethylidene-1,3-cyclohexanediones were also isolated. From the potassium salt of 2-formyldimedone and 2-carboxyphenylhydrazine hydrochloride, 2-(2-carboxyphenyl)hydrazinomethylene-5,5-dimethyl-1,3-cyclohexanedione was obtained, the cyclization of which in ethanol in the presence of HCl led to 1-(2-carboxyphenyl)- and 1-(2-ethoxycarbonylphenyl)-6,6-dimethyl-4-oxo-4,5,6,7-tetrahydroindazole.     

Optically active antifungal azoles. XIII. Synthesis of stereoisomers and metabolites of 1-[(1R,2R)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-3-[4-(1H-1-tetrazolyl)phenyl]-2-imidazolidinone (TAK-456)

1-[(1R,2R)-2-(2,4-Difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-3-[4-(1H-1-tetrazolyl)phenyl]-2-imidazolidinone [(1R,2R)-1: TAK-456] is a new antifungal agent selected as a candidate for clinical trials. The three stereoisomers [(1S,2R)-, (1S,2S)- and (1R,2S)-1] of this compound were prepared as authentic samples to determine the enantiomeric and diastereomeric purity of TAK-456 as well as to compare their in vitro antifungal activity. Pharmacokinetic studies of TAK-456 using rats identified the existence of metabolites in the liver homogenate. The structures of the major metabolites were assigned as 4-hydroxy-2-imidazolidinone (3) and/or 5-hydroxy-2-imidazolidinone (4), based on HPLC and LC/MS/MS analyses. These hydroxylated compounds, 3 and 4, were prepared by reduction of the corresponding imidazolidinediones, 11 and 12, and confirmed to be identical to the metabolites by HPLC. In vitro antifungal activities of the three stereoisomers and the synthesized metabolites were considerably weaker than TAK-456.     

Synthesis of 1-alkoxy-3-(2-hydroxyethyl)-1-triazene 2-oxides

Synthetic procedure to access the first representatives of a new series of 3-monosubstitued functional derivatives of 1-alkoxy-1-triazene 2-oxides, i.e., 1-alkoxy-3-(2-hydroxyethyl)- and 1-alkoxy-3-(2-acetoxyethyl)-1-triazene 2-oxides, were elaborated. 1-Alkoxy-3,3-bis(2-hydroxyethyl)-1-triazene 2-oxides were used to derive 3-(2-acetoxyethyl)-, 3-(2-bromoethyl)- and 3-(2-cyanoethyl)substituted 1-alkoxy-3-(2-acetoxyethyl)-1-triazene 2-oxides.